There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
NCT05497778
Recruiting
To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Pancreas Cancer
Register for Updates
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296
Recruiting
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Adenocarcinoma
Register for Updates
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
NCT05654922
Recruiting
The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone. The main question it aims to answer are: * Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant * To evaluate the effectiveness of ARINA-1 on improving quality of life decline and preventing or delaying the use of augmented immunosuppression in partic... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Pre-Bronchiolitis Obliterans Syndrome
Register for Updates
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
07/21/2025
Locations: Helios Clinical Research - Houston, Houston, Texas +1 locations
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Register for Updates
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
NCT06445959
Recruiting
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mutant IDH1 Inhibitor Olutasidenib
Register for Updates
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
NCT06458712
Recruiting
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Register for Updates
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
NCT06597734
Recruiting
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005
Recruiting
This is a Phase 1 and Phase 2 study to determine the safety profile, RDR and/or MTD, DLT, PK/PD, and preliminary antitumor activity of INV-9956 in adult patients with advanced mCRPC.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Next Oncology - Houston, Houston, Texas
Conditions: Advanced Metastatic Castration Resistant Prostate Cancer
Register for Updates
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine
NCT06628622
Recruiting
This study is open to men between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence. People can join the study if they currently take a medicine called buprenorphine. People with opioid dependence can act on impulse, which can lead to risky behaviours. The purpose of this study is to find out whether a medicine called BI 1356225 improves impulse control in men with opioid dependence. Participants are put into 2 groups by ch... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/21/2025
Locations: ERG Clinical Research - Houston, Houston, Texas
Conditions: Opioid Use Disorder
Register for Updates
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617
Recruiting
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Register for Updates
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
NCT06811233
Recruiting
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates